Alder BioPharmaceuticals (Alder BioPharmaceuticals) Cash Conversion Cycle : 0.00 (As of Jun. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Alder BioPharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2019 was 0.
Alder BioPharmaceuticals's Days Inventory for the three months ended in Jun. 2019 was 0.
Alder BioPharmaceuticals's Days Payable for the three months ended in Jun. 2019 was 0.
Therefore, Alder BioPharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2019 was 0.00.

Alder BioPharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Alder BioPharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Cash Conversion Cycle Chart

Alder BioPharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Cash Conversion Cycle

Get a 7-Day Free Trial

1.43

-21,344.43

-1,799.07

Alder BioPharmaceuticals Quarterly Data
	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19
Cash Conversion Cycle	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Alder BioPharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, Alder BioPharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alder BioPharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alder BioPharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Alder BioPharmaceuticals's Cash Conversion Cycle falls into.

Alder BioPharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Alder BioPharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2018 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Alder BioPharmaceuticals's Cash Conversion Cycle for the quarter that ended in Jun. 2019 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+	0	-	0
	=	0.00

Alder BioPharmaceuticals (NAS:ALDR) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Alder BioPharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

11804 North Creek Parkway South, Bothell, WA, USA, 98011

Website

http://www.alderbio.com

Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

Executives

Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S	10 percent owner	9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno	director
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby	director, officer: President and CEO	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston	director	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green	director	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	director	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton	officer: Chief Business Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter	officer: Interim Chief Medical Officer	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620